SITC Resource Library

On January 7, 2020, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma (RCC)" during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
• Dena Battle – KCCure
• David McDermott, MD – Beth Israel Deaconess Medical Center
• Brian Rini, MD – Vanderbilt University Medical Center

• SITC's Cancer Immunotherapy Guidelines on immunotherapy for the treatment of renal cell carcinoma
• New FDA approvals and the role of patient biomarker testing in optimizing treatment selection
• Unique case studies that may require adaptation of cancer immunotherapy regimens
• How best to manage immune-related adverse events

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.

This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.

Please note that the on-demand webinar is not available for continuing education credits